- Home
- OCGN vs XFOR Comparison
OCGN vs XFOR Comparison
Compare OCGN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- XFOR
- Stock Information
- Founded
- OCGN 2013
- XFOR 2014
- Country
- OCGN United States
- XFOR United States
- Employees
- OCGN N/A
- XFOR N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCGN Health Care
- XFOR Health Care
- Exchange
- OCGN Nasdaq
- XFOR Nasdaq
- Market Cap
- OCGN 321.7M
- XFOR 332.3M
- IPO Year
- OCGN N/A
- XFOR N/A
- Fundamental
- Price
- OCGN $1.19
- XFOR $3.70
- Analyst Decision
- OCGN Strong Buy
- XFOR Strong Buy
- Analyst Count
- OCGN 2
- XFOR 3
- Target Price
- OCGN $7.00
- XFOR $34.67
- AVG Volume (30 Days)
- OCGN 3.2M
- XFOR 604.7K
- Earning Date
- OCGN 11-05-2025
- XFOR 11-05-2025
- Dividend Yield
- OCGN N/A
- XFOR N/A
- EPS Growth
- OCGN N/A
- XFOR N/A
- EPS
- OCGN N/A
- XFOR N/A
- Revenue
- OCGN $5,370,000.00
- XFOR $33,979,000.00
- Revenue This Year
- OCGN N/A
- XFOR $1,307.51
- Revenue Next Year
- OCGN N/A
- XFOR N/A
- P/E Ratio
- OCGN N/A
- XFOR N/A
- Revenue Growth
- OCGN 14.26
- XFOR 2925.74
- 52 Week Low
- OCGN $0.52
- XFOR $1.35
- 52 Week High
- OCGN $1.90
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- OCGN 36.58
- XFOR 51.95
- Support Level
- OCGN $1.14
- XFOR $3.49
- Resistance Level
- OCGN $1.22
- XFOR $3.90
- Average True Range (ATR)
- OCGN 0.08
- XFOR 0.23
- MACD
- OCGN -0.01
- XFOR -0.01
- Stochastic Oscillator
- OCGN 28.79
- XFOR 67.19
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.